Childrens Mercy Hospital
- Type
- Teaching hospital
- Where
- KANSAS CITY, MO
- Medicare CCN
- 263302
- Received
- $2,671,729 in 1,133 records, 2024 ($213,633 general, $2,458,095 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE CHILDRENS MERCY HOSPITAL CORPORATION Fuzzy (name and state)
- Federal award recipient: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
- Nonprofit: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 36 | $213,633 |
| 2024 | Research payment | 1,097 | $2,458,095 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,097 | $2,458,095 |
| Grant | 4 | $92,813 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 8 | $85,045 |
| Long term medical supply or device loan | 10 | $23,034 |
| Space rental or facility fees (teaching hospital only) | 6 | $7,900 |
| Consulting Fee | 5 | $3,470 |
| Charitable Contribution | 1 | $750 |
| Honoraria | 1 | $586 |
| Debt forgiveness | 1 | $34 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $16,890 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | LIGHTBEAM-U01 Substudy 01B# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination Wit | 2024 |
| 2024-12-31 | Stryker Corporation | $12,978 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Bayer Healthcare Pharmaceuticals Inc. | $5,037 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY 948862, A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety a | 2024 |
| 2024-12-31 | Stryker Corporation | $4,087 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $2,651 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $1,485 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | LIGHTBEAM-U01 Substudy 01B# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination Wit | 2024 |
| 2024-12-31 | Linvatec Corporation | $1,440 | Long term medical supply or device loan | In-kind items and services | HANDSTAND Device, ORTHOPEDIC SURGERY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $170 | Research payment | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2024 |
| 2024-12-31 | Masimo Corporation | $142 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $142 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $142 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $142 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $97 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Ph | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $27 | Research payment | Cash or cash equivalent | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2024 |
| 2024-12-23 | Bayer Healthcare Pharmaceuticals Inc. | $2,556 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY 948862, A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety a | 2024 |
| 2024-12-23 | Eli Lilly and Company | $476 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGR | 2024 | |
| 2024-12-20 | Novo Nordisk AS | $5,750 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-12-20 | Novo Nordisk AS | $1,080 | Research payment | Cash or cash equivalent | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-12-19 | ALBIREO PHARMA, INC. | $3,850 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary A | 2024 |
| 2024-12-19 | ALBIREO PHARMA, INC. | $2,048 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary A | 2024 |
| 2024-12-18 | Ultragenyx Pharmaceutical Inc. | $1,541 | Research payment | Cash or cash equivalent | UX143-CL314 | 2024 | |
| 2024-12-18 | ACADIA Pharmaceuticals Inc | $1,522 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2024 |
| 2024-12-17 | BioFire Diagnostics, LLC | $1,000 | Research payment | In-kind items and services | BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini Device, Diagnostics | SpotFire R Mini ANS Prospective Study | 2024 |
| 2024-12-16 | Gen-Probe, Inc. | $9,000 | Research payment | Cash or cash equivalent | APTIMA Device, Diagnostics | 655-A10960-001 | 2024 |
| 2024-12-16 | Edwards Lifesciences Corporation | $8,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2024 |
| 2024-12-16 | Edwards Lifesciences Corporation | $568 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2024 |
| 2024-12-13 | Catalent Pharma Solutions, LLC | $750 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-12-12 | ALBIREO PHARMA, INC. | $2,050 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-12 | Novo Nordisk AS | $13 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-12-11 | ACADIA Pharmaceuticals Inc | $27,666 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2024 |
| 2024-12-11 | ACADIA Pharmaceuticals Inc | $2,496 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-303 | 2024 |
| 2024-12-10 | Dexcom, Inc. | $9,550 | Research payment | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2024 |
| 2024-12-10 | Ultragenyx Pharmaceutical Inc. | $6,057 | Research payment | Cash or cash equivalent | UX143-CL301 | 2024 | |
| 2024-12-06 | BioFire Diagnostics, LLC | $33,706 | Research payment | Cash or cash equivalent | BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini Device, Diagnostics | SpotFire R Mini ANS Prospective Study | 2024 |
| 2024-12-06 | Gen-Probe, Inc. | $9,100 | Research payment | Cash or cash equivalent | APTIMA Device, Diagnostics | 655-A10960-001 | 2024 |
| 2024-12-05 | ALBIREO PHARMA, INC. | $75 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2024 |
| 2024-12-04 | Immedica Pharma US, Inc. | $11,167 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-12-03 | Ultragenyx Pharmaceutical Inc. | $2,351 | Research payment | Cash or cash equivalent | UX143-CL314 | 2024 | |
| 2024-12-03 | Ultragenyx Pharmaceutical Inc. | $1,624 | Research payment | Cash or cash equivalent | UX143-CL301 | 2024 | |
| 2024-12-03 | Medtronic, Inc. | $1,500 | Research payment | Cash or cash equivalent | INVOS Device, Cerebral/Somatic Oximetry | INVOS CathLab | 2024 |
| 2024-12-01 | BioMarin Pharmaceutical Inc. | $2,555 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VOXZOGO 1.2mg Drug, Achondroplasia | 2024 | |
| 2024-11-27 | GE HEALTHCARE | $1,225 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-27 | GE HEALTHCARE | $700 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-26 | Ultragenyx Pharmaceutical Inc. | $9,684 | Research payment | Cash or cash equivalent | UX143-CL301 | 2024 | |
| 2024-11-26 | Amgen Inc. | $3,600 | Research payment | Cash or cash equivalent | Kyprolis Drug, Oncology | Kyprolis CFZ Ph1/2 Pediatric ALL | 2024 |
| 2024-11-26 | Immedica Pharma US, Inc. | $1,500 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-11-26 | Draeger Medical Systems, Inc | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Babylog VN800 Device, Pulmonary/Respiratory Diseases | 2024 | |
| 2024-11-20 | Novo Nordisk AS | $1,080 | Research payment | Cash or cash equivalent | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-19 | Ultragenyx Pharmaceutical Inc. | $3,082 | Research payment | Cash or cash equivalent | UX143-CL314 | 2024 | |
| 2024-11-19 | AMAG Pharmaceuticals, Inc. | $40 | Research payment | Cash or cash equivalent | FERAHEME Drug, For the treatment of iron deficiency anemia associated with chronic kidney disease | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHA | 2024 |
| 2024-11-14 | Edwards Lifesciences Corporation | $5,600 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2024 |
| 2024-11-14 | Edwards Lifesciences Corporation | $177 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-14 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-13 | Medtronic, Inc. | $3,699 | Research payment | Cash or cash equivalent | INVOS Device, Cerebral/Somatic Oximetry | INVOS CathLab | 2024 |
| 2024-11-13 | Travere Therapeutics, Inc. | $90 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2024 | |
| 2024-11-12 | Immedica Pharma US, Inc. | $22,600 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-11-12 | Edwards Lifesciences Corporation | $4,590 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2024 |
| 2024-11-12 | Immedica Pharma US, Inc. | $3,070 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-11-12 | Ultragenyx Pharmaceutical Inc. | $2,351 | Research payment | Cash or cash equivalent | UX143-CL314 | 2024 | |
| 2024-11-12 | Ultragenyx Pharmaceutical Inc. | $2,247 | Research payment | Cash or cash equivalent | UX143-CL301 | 2024 | |
| 2024-11-12 | AMAG Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | FERAHEME Drug, For the treatment of iron deficiency anemia associated with chronic kidney disease | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHA | 2024 |
| 2024-11-12 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2024 |
| 2024-11-07 | Bayer Healthcare Pharmaceuticals Inc. | $3,102 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY 948862, A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety a | 2024 |
| 2024-11-07 | BioFire Diagnostics, LLC | $300 | Research payment | In-kind items and services | BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini Device, Diagnostics | SpotFire R Mini ANS Prospective Study | 2024 |
| 2024-11-06 | Novo Nordisk AS | $15,250 | Research payment | Cash or cash equivalent | Alhemo Drug, Hemophilia | NN7415-4616 | 2024 |
| 2024-11-06 | Rhythm Pharmaceuticals, Inc. | $1,744 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-11-06 | Rhythm Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-11-06 | Rhythm Pharmaceuticals, Inc. | $153 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-11-06 | Rhythm Pharmaceuticals, Inc. | $78 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-11-05 | Ultragenyx Pharmaceutical Inc. | $3,399 | Research payment | Cash or cash equivalent | UX143-CL301 | 2024 | |
| 2024-11-05 | Gilead Sciences, Inc. | $61 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2024 |
| 2024-11-04 | Ultragenyx Pharmaceutical Inc. | $15,145 | Research payment | Cash or cash equivalent | UX143-CL301 | 2024 | |
| 2024-11-04 | SANOFI US SERVICES INC. | $541 | Research payment | Cash or cash equivalent | TZIELD Biological, Endocrine & Metabolic Diseases | A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a | 2024 |
| 2024-10-31 | Novo Nordisk AS | $2,388 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2024 |
| 2024-10-31 | Novo Nordisk AS | $1,926 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2024 |
| 2024-10-30 | ACADIA Pharmaceuticals Inc | $15,539 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2024 |
| 2024-10-30 | PFIZER INC. | $11,471 | Research payment | Cash or cash equivalent | LOW INTERVENTIONAL COHORT STUDY OF MYOCARDITISPERICARDITIS ASSOCIATED WITH COMIRNATY IN PERSONS LESS THAN 21 YEARS OF AG | 2024 | |
| 2024-10-30 | PFIZER INC. | $3,300 | Research payment | Cash or cash equivalent | LOW INTERVENTIONAL COHORT STUDY OF MYOCARDITISPERICARDITIS ASSOCIATED WITH COMIRNATY IN PERSONS LESS THAN 21 YEARS OF AG | 2024 | |
| 2024-10-30 | PFIZER INC. | $1,296 | Research payment | Cash or cash equivalent | LOW INTERVENTIONAL COHORT STUDY OF MYOCARDITISPERICARDITIS ASSOCIATED WITH COMIRNATY IN PERSONS LESS THAN 21 YEARS OF AG | 2024 | |
| 2024-10-30 | Ultragenyx Pharmaceutical Inc. | $1,215 | Research payment | Cash or cash equivalent | UX143-CL301 | 2024 | |
| 2024-10-30 | Ultragenyx Pharmaceutical Inc. | $558 | Research payment | Cash or cash equivalent | UX143-CL301 | 2024 | |
| 2024-10-30 | Ultragenyx Pharmaceutical Inc. | $82 | Research payment | Cash or cash equivalent | UX143-CL301 | 2024 | |
| 2024-10-30 | Ultragenyx Pharmaceutical Inc. | $36 | Research payment | Cash or cash equivalent | UX143-CL301 | 2024 | |
| 2024-10-29 | Dexcom, Inc. | $2,794 | Research payment | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2024 |
| 2024-10-25 | Hoffmann-La Roche Limited | $3,350 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-10-25 | National Marrow Donor Program | $3,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-10-25 | Hoffmann-La Roche Limited | $2,866 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-10-25 | Hoffmann-La Roche Limited | $1,750 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-10-25 | Hoffmann-La Roche Limited | $750 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-10-25 | Hoffmann-La Roche Limited | $103 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-10-23 | Rhythm Pharmaceuticals, Inc. | $3,252 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-10-23 | Rhythm Pharmaceuticals, Inc. | $3,252 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-10-23 | Rhythm Pharmaceuticals, Inc. | $3,252 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-10-23 | Rhythm Pharmaceuticals, Inc. | $2,929 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-10-23 | Rhythm Pharmaceuticals, Inc. | $2,929 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-10-23 | Rhythm Pharmaceuticals, Inc. | $2,539 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-10-23 | Rhythm Pharmaceuticals, Inc. | $2,539 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2024 | |
| 2024-10-22 | Gilead Sciences, Inc. | $2,339 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2024 |
| 2024-10-18 | Hoffmann-La Roche Limited | $2,866 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-10-18 | Hoffmann-La Roche Limited | $103 | Research payment | Cash or cash equivalent | Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | 2024 | |
| 2024-10-17 | Edwards Lifesciences Corporation | $11,730 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2024 |
| 2024-10-17 | ALBIREO PHARMA, INC. | $5,776 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2024 |
| 2024-10-17 | Edwards Lifesciences Corporation | $5,200 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2024 |
The latest 200 records of 1,133.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kansas City, MO, county Jackson County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Kansas City, MO | County Jackson County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 510,612 | 719,976 | 6,191,814 |
| Population, 2020 census P1 | 508,090 | 717,204 | 6,154,913 |
| Median age B01002 | 35.8 | 37.0 | 39.0 |
| Under 18 B01001 | 22.5% | 23.3% | 22.3% |
| 65 and over B01001 | 14.3% | 15.9% | 17.9% |
| Households B11001 | 221,979 | 306,798 | 2,508,227 |
| Foreign born B05002 | 8.6% | 6.6% | 4.5% |
| Median household income B19013 | $69,166 | $68,577 | $70,702 |
| Median family income B19113 | $92,934 | $90,585 | $91,360 |
| Per capita income B19301 | $41,393 | $39,559 | $39,695 |
| Poverty rate B17001 | 14.6% | 14.1% | 12.6% |
| Unemployment rate B23025 | 4.4% | 4.7% | 4.0% |
| Civilian labor force B23025 | 279,828 | 381,433 | 3,120,639 |
| Mean commute (minutes) B08013 | 21.7 | 23.4 | 23.5 |
| Bachelor's degree or higher B15003 | 38.4% | 34.0% | 32.4% |
| Housing units B25001 | 245,346 | 336,288 | 2,825,287 |
| Owner-occupied B25003 | 55.4% | 59.1% | 68.1% |
| Renters B25003 | 44.6% | 40.9% | 31.9% |
| Median home value B25077 | $242,900 | $230,500 | $230,300 |
| Median gross rent B25064 | $1,238 | $1,197 | $1,033 |
| White, not Hispanic B03002 | 54.0% | 59.3% | 76.3% |
| Black B03002 | 25.2% | 22.0% | 10.9% |
| Hispanic or Latino B03002 | 12.5% | 11.4% | 5.2% |
| Asian B03002 | 2.8% | 1.8% | 2.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, MO.
Comments